CoChat

Reactive cholangiocyte-derived ORM2 drives a pathogenic modulation of the injured biliary niche through macrophage reprogramming

Open access
Liu, Hanyang, Yin, Guo, Franco Leonardi, Bianca, Lan, Tian, Ait Ahmed, Yeni, Berger, Hilmar, Kohlhepp, Marlene Sophia, Amiridze, Natalja, Martagón Calderón, Natalia, Frau, Carla, Vallier, Ludovic, Rezvani, Milad, Tacke, Frank, Guillot, Adrien · 2025 · Gut

The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.

Abstract

Background: Injured or reactive biliary epithelial cells participate in most chronic liver injuries in a process referred to as ductular reaction, which involves multicellular interactions with marked local infiltration of macrophages and fibrogenic cell activation. The direct roles of biliary epithelial cells in shaping their cellular niche remain unknown. Objective: We aimed at investigating the effects of biliary epithelial cell-derived acute phase response protein orosomucoid 2 (ORM2) in shaping monocyte/macrophage response to liver injury. Design: Transcriptome data sets from human and mouse livers were used, results were confirmed with multiplex immunofluorescence. A multicellular biliary-niche-on-a-chip derived from primary liver and blood cells (wild-type, Mdr2 −/− mice) was established to model ductular reaction. Human blood cells collected from healthy donors and intrahepatic cholangiocyte organoids derived from normal and cirrhotic liver patients were used. Results: Our transcriptome data set and multiplex immunofluorescence analyses indicated a previously unrecognised involvement of the acute phase response protein ORM2 in ductular reactions in both human and mouse livers. ORM2 gene expression was increased in biliatresone-challenged, bile acid-challenged and acetaminophen-challenged cholangiocytes. Cholangiocyte-derived ORM2 induced unique transcriptome changes and functional adaptation of liver macrophages. ORM2-activated macrophages exacerbated cholangiocyte cell stress and Orm2 expression, but also tended to promote fibrogenic activation of hepatic stellate cells. Mechanistically, ORM2 effects were mediated by an inositol 1,4,5-trisphosphate receptor type 2-dependent calcium pathway. Conclusion: This study reveals a paracrine communication circuit during ductular reaction, in which reactive cholangiocyte-derived ORM2 reprogrammes liver macrophages, participating in a pathogenic remodelling of the immune biliary niche.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/gutjnl-2024-334425

Cites

67 of 67 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 ORM2 is upregulated in cholangiocytes but downregulated in hepatocytes during liver injury. (A) Ckb, Fam166b, Onecut1, Orm2 and Adam11 were upregulated in both acutely (ihCD59BEG-TG mice challenged by acute BEC injury for 48 hours, data set ID: PRJNA510784) and chronically (32-week-old dnTGFβRII mice, data set ID: GSE202676; 29-week HFD fed mice, data set ID: GSE217739) injured mouse BECs. Upregulated DEGs were identified as log2(fold change) >0.5, p<0.05. (B) Gene expression changes of Adam11 and Orm2 in injured livers from diverse mouse models (injured vs healthy) and human samples (diseases vs healthy). Bulk RNA sequencing data was obtained from the GepLiver database and GEO data sets. (C) Gene expression changes of Orm2 in single-cell resolved human liver samples with MASLD, liver cirrhosis and PSC. scRNA-seq and snRNA-seq data were obtained from the GepLiver database and GEO data sets (ID: GSE247128 and GSE243977). ‘X’ in the block represents undetectable data. (D) Immunofluorescent staining illustrated the associations among hepatocytes (HepPar1+), BECs (CK7+), monocytes/macrophages (IBA1+) and ORM2 expression in human liver samples (normal, MALSD and PSC). Relative ORM2 staining was illustrated with highlighted portal areas. (E) ORM2 expression in single hepatocytes and BECs in human liver samples (normal, MALSD and PSC) was assessed according to the immunofluorescent staining analyses. (F) Significant correlations (Spearman’s, p<0.05) among staining intensity of ORM2, CK7 and CK19, neighbouring IBA1+ cells (<100 µm) and minimum distance to IBA1+ cells were illustrated in a heatmap. (G) Gene expression of Orm2 in WT mouse primary BECs on biliatresone and CDCA treatments (vs untreated). (H) Protein expression of ORM2 in mouse primary BECs on biliatresone illustrated in fluorescent staining and (I) quantitative analysis. (J) Gene expression of Orm2 in WT mouse primary hepatocytes on FFAs, APAP and biliatresone treatments (vs untreated). (K) Protein expression of ORM2 in mouse primary hepatocytes on biliatresone illustrated in fluorescent staining and (L) quantitative analysis. Sample sizes: (D–F) n=1–4 per group; (G–K) n=4 per group. APAP, acetaminophen; B/(m)BEC, (mouse) biliary epithelial cell; BSA, bovine serum albumin; CDCA, chenodeoxycholic acid; DDC, 3,5-diethoxycarbonyl-1,4-dihydrocollidine; DEG, differentially expressed gene; F0/2/4, fibrosis stage-0/2/4; FFAs, free fatty acids; H/(m)HepaC, (mouse) hepatocyte; HFD, high-fat diet; IntraC/ExtraC, intracellular/extracellular; MASLD, metabolic dysfunction associated steatotic liver diseases; MASH, metabolic dysfunction associated steatohepatitis; PSC, primary sclerosing cholangitis; OA, oleic acid; ORM2, orosomucoid 2; sc/snRNA, single-cell/single-nuclei RNA; WT, wild-type. One-way analysis of variance followed by Tukey’s multiple comparison test and unpaired Student’s t-tests were performed. *p<0.05 as indicated or as compared with controls.
Figure 1 ORM2 is upregulated in cholangiocytes but downregulated in hepatocytes during liver injury. (A) Ckb, Fam166b, Onecut1, Orm2 and Adam11 were upregulated in both acutely (ihCD59BEG-TG mice challenged by acute BEC injury for 48 hours, data set ID: PRJNA510784) and chronically (32-week-old dnTGFβRII mice, data set ID: GSE202676; 29-week HFD fed mice, data set ID: GSE217739) injured mouse BECs. Upregulated DEGs were identified as log2(fold change) >0.5, p<0.05. (B) Gene expression changes of Adam11 and Orm2 in injured livers from diverse mouse models (injured vs healthy) and human samples (diseases vs healthy). Bulk RNA sequencing data was obtained from the GepLiver database and GEO data sets. (C) Gene expression changes of Orm2 in single-cell resolved human liver samples with MASLD, liver cirrhosis and PSC. scRNA-seq and snRNA-seq data were obtained from the GepLiver database and GEO data sets (ID: GSE247128 and GSE243977). ‘X’ in the block represents undetectable data. (D) Immunofluorescent staining illustrated the associations among hepatocytes (HepPar1+), BECs (CK7+), monocytes/macrophages (IBA1+) and ORM2 expression in human liver samples (normal, MALSD and PSC). Relative ORM2 staining was illustrated with highlighted portal areas. (E) ORM2 expression in single hepatocytes and BECs in human liver samples (normal, MALSD and PSC) was assessed according to the immunofluorescent staining analyses. (F) Significant correlations (Spearman’s, p<0.05) among staining intensity of ORM2, CK7 and CK19, neighbouring IBA1+ cells (<100 µm) and minimum distance to IBA1+ cells were illustrated in a heatmap. (G) Gene expression of Orm2 in WT mouse primary BECs on biliatresone and CDCA treatments (vs untreated). (H) Protein expression of ORM2 in mouse primary BECs on biliatresone illustrated in fluorescent staining and (I) quantitative analysis. (J) Gene expression of Orm2 in WT mouse primary hepatocytes on FFAs, APAP and biliatresone treatments (vs untreated). (K) Protein expression of ORM2 in mouse primary hepatocytes on biliatresone illustrated in fluorescent staining and (L) quantitative analysis. Sample sizes: (D–F) n=1–4 per group; (G–K) n=4 per group. APAP, acetaminophen; B/(m)BEC, (mouse) biliary epithelial cell; BSA, bovine serum albumin; CDCA, chenodeoxycholic acid; DDC, 3,5-diethoxycarbonyl-1,4-dihydrocollidine; DEG, differentially expressed gene; F0/2/4, fibrosis stage-0/2/4; FFAs, free fatty acids; H/(m)HepaC, (mouse) hepatocyte; HFD, high-fat diet; IntraC/ExtraC, intracellular/extracellular; MASLD, metabolic dysfunction associated steatotic liver diseases; MASH, metabolic dysfunction associated steatohepatitis; PSC, primary sclerosing cholangitis; OA, oleic acid; ORM2, orosomucoid 2; sc/snRNA, single-cell/single-nuclei RNA; WT, wild-type. One-way analysis of variance followed by Tukey’s multiple comparison test and unpaired Student’s t-tests were performed. *p<0.05 as indicated or as compared with controls.CC BY · PubMed Central
Figure 2 Evaluating influences of ORM2 in hepatic microenvironment in BoC and LoC models. (A) Gene expression of Mki67, Orm2 and Ccl2 in Od-mBECs generated from WT and Mdr2−/− mice. (B) 4-day kinetics of cell proliferation in Od-mBECs generated from WT and Mdr2−/− mice. (C) Scheme: using BoC and LoC models to recapitulate hepatic microenvironment and investigate influences of Orm2. (D) Experimental strategies of BoC and LoC were illustrated in a schematic figure. (E) HSC accumulation on siCtrl and siOrm2 transfection in BECs was illustrated in fluorescent staining (F-actin+) and (F) quantitative analysis. (G) Collagen production (COL1A1+) and cell proliferation (Ki67+) were illustrated in fluorescent staining and (H) (I) quantitative analyses. (J) CIC accumulation (F-actin+) to the BoC membrane was illustrated in fluorescent staining and (K) quantitative analysis. (L) Lipid deposition (BODIPY+) was illustrated in fluorescent staining and (M) quantitative analysis. Levels of (N) triglycerides and (O) AST were measured in LoC cells on FFAs treatment (HepaC-siCtrl vs HepaC-siOrm2). (P) Gene expression of representative inflammation-associated, fibrogenesis-associated, adhesion-associated and tight junction-associated factors were measured in BoC cells (BEC-siCtrl vs BEC-siOrm2). (Q) Gene expression of representative inflammation-associated, fibrogenesis-associated, adhesion-associated factors were measured in LoC cells on FFAs treatment (HepaC-siCtrl vs HepaC-siOrm2). Sample sizes: n=3 per group. AST, aspartate transaminase; BoC, biliary niche-on-a-chip; CIC, circulating immune cell; COL1A1, collagen type I alpha 1 chain; Ctrl, control; FFA, free fatty acid; HFD, high-fat diet; HSC, hepatic stellate cell; LoC, liver-on-a-chip; (m)BEC, (mouse) biliary epithelial cell; (m)HepaC, (m)hepatocyte; Od, organoid-derived; ORM2, orosomucoid 2; WT, wild type. Unpaired Student’s t-tests were performed. *p<0.05 as indicated or as compared with controls.
Figure 2 Evaluating influences of ORM2 in hepatic microenvironment in BoC and LoC models. (A) Gene expression of Mki67, Orm2 and Ccl2 in Od-mBECs generated from WT and Mdr2−/− mice. (B) 4-day kinetics of cell proliferation in Od-mBECs generated from WT and Mdr2−/− mice. (C) Scheme: using BoC and LoC models to recapitulate hepatic microenvironment and investigate influences of Orm2. (D) Experimental strategies of BoC and LoC were illustrated in a schematic figure. (E) HSC accumulation on siCtrl and siOrm2 transfection in BECs was illustrated in fluorescent staining (F-actin+) and (F) quantitative analysis. (G) Collagen production (COL1A1+) and cell proliferation (Ki67+) were illustrated in fluorescent staining and (H) (I) quantitative analyses. (J) CIC accumulation (F-actin+) to the BoC membrane was illustrated in fluorescent staining and (K) quantitative analysis. (L) Lipid deposition (BODIPY+) was illustrated in fluorescent staining and (M) quantitative analysis. Levels of (N) triglycerides and (O) AST were measured in LoC cells on FFAs treatment (HepaC-siCtrl vs HepaC-siOrm2). (P) Gene expression of representative inflammation-associated, fibrogenesis-associated, adhesion-associated and tight junction-associated factors were measured in BoC cells (BEC-siCtrl vs BEC-siOrm2). (Q) Gene expression of representative inflammation-associated, fibrogenesis-associated, adhesion-associated factors were measured in LoC cells on FFAs treatment (HepaC-siCtrl vs HepaC-siOrm2). Sample sizes: n=3 per group. AST, aspartate transaminase; BoC, biliary niche-on-a-chip; CIC, circulating immune cell; COL1A1, collagen type I alpha 1 chain; Ctrl, control; FFA, free fatty acid; HFD, high-fat diet; HSC, hepatic stellate cell; LoC, liver-on-a-chip; (m)BEC, (mouse) biliary epithelial cell; (m)HepaC, (m)hepatocyte; Od, organoid-derived; ORM2, orosomucoid 2; WT, wild type. Unpaired Student’s t-tests were performed. *p<0.05 as indicated or as compared with controls.CC BY · PubMed Central
Figure 3 A complete liver-on-a-chip containing both BECs and hepatocytes suggests that ORM2 regulates pathogenic monocyte recruitment. (A) Seeding sequence and experimental approach to generate a complete liver-on-a-chip. (B) Cell seeding and identities were confirmed by immunocytochemistry in the complete liver-on-a-chip. (C) Enlarged areas depict desmin+ and CK7+ cell. (D) Gating strategy applied for flow cytometry evaluation of circulating immune cells in the complete liver-on-a-chip. Monocytes (live CD45+CD19−TCR-beta−Ly6G−F4/80+CD11b+CX3CR1high) and Ly6Chigh monocytes were numbered in the complete liver-on-a-chip after either (E) BEC-targeted, or (F) hepatocyte-targeted Orm2 silencing. BECs, biliary epithelial cells; CICs, circulating immune cells; CK7, cytokeratin 7; HSCs, hepatic stellate cells; ORM2, orosomucoid 2. Paired Student’s t-tests were used. *p<0.05 as indicated.
Figure 3 A complete liver-on-a-chip containing both BECs and hepatocytes suggests that ORM2 regulates pathogenic monocyte recruitment. (A) Seeding sequence and experimental approach to generate a complete liver-on-a-chip. (B) Cell seeding and identities were confirmed by immunocytochemistry in the complete liver-on-a-chip. (C) Enlarged areas depict desmin+ and CK7+ cell. (D) Gating strategy applied for flow cytometry evaluation of circulating immune cells in the complete liver-on-a-chip. Monocytes (live CD45+CD19−TCR-beta−Ly6G−F4/80+CD11b+CX3CR1high) and Ly6Chigh monocytes were numbered in the complete liver-on-a-chip after either (E) BEC-targeted, or (F) hepatocyte-targeted Orm2 silencing. BECs, biliary epithelial cells; CICs, circulating immune cells; CK7, cytokeratin 7; HSCs, hepatic stellate cells; ORM2, orosomucoid 2. Paired Student’s t-tests were used. *p<0.05 as indicated.CC BY · PubMed Central
Figure 4 ORM2 reshapes transcriptome profiles in liver macrophages. (A) Gene expression of macrophage phenotype-associated markers was measured in human THP-1 cell line, hMoMF, mLMF and mBMDM (ORM2-treated vs Ctrl). (B) Significantly upregulated and downregulated DEGs in mLMF by bulk RNA-seq analysis were illustrated in the volcano plot (ORM2-treated vs Ctrl). (C) Function enrichment analysis (GO-BP and KEGG) on significantly upregulated and downregulated DEGs in mLMF by bulk RNA-seq analysis was illustrated (ORM2-treated vs Ctrl). (D) Gene expression changes of pro-inflammatory and anti-inflammatory macrophage phenotype-associated markers in mLMF by bulk RNA-seq analysis were illustrated in the radar plot (ORM2-treated vs Ctrl). (E) Overlapped significantly upregulated DEGs in mLMF from diverse bulk RNA-seq data sets (GSE273509 and GSE86397) were illustrated (vs Ctrl). Sample sizes: (A) n=4 per group; (B–E) ORM2-treated (n=4) versus Ctrl (n=5). DEG, differentially expressed gene; GO-BP, Gene Ontology-biological processes; hMoMF, human monocyte-derived macrophages; KEGG, Kyoto Encyclopedia of Genes and Genomes; mLMF, mouse liver macrophages; mBMDM, mouse bone marrow-derived macrophages; mRNA, messenger RNA; ORM2, orosomucoid 2; RNA-seq, RNA sequencing. Unpaired Student’s t-tests were used. *Represents p<0.05.
Figure 4 ORM2 reshapes transcriptome profiles in liver macrophages. (A) Gene expression of macrophage phenotype-associated markers was measured in human THP-1 cell line, hMoMF, mLMF and mBMDM (ORM2-treated vs Ctrl). (B) Significantly upregulated and downregulated DEGs in mLMF by bulk RNA-seq analysis were illustrated in the volcano plot (ORM2-treated vs Ctrl). (C) Function enrichment analysis (GO-BP and KEGG) on significantly upregulated and downregulated DEGs in mLMF by bulk RNA-seq analysis was illustrated (ORM2-treated vs Ctrl). (D) Gene expression changes of pro-inflammatory and anti-inflammatory macrophage phenotype-associated markers in mLMF by bulk RNA-seq analysis were illustrated in the radar plot (ORM2-treated vs Ctrl). (E) Overlapped significantly upregulated DEGs in mLMF from diverse bulk RNA-seq data sets (GSE273509 and GSE86397) were illustrated (vs Ctrl). Sample sizes: (A) n=4 per group; (B–E) ORM2-treated (n=4) versus Ctrl (n=5). DEG, differentially expressed gene; GO-BP, Gene Ontology-biological processes; hMoMF, human monocyte-derived macrophages; KEGG, Kyoto Encyclopedia of Genes and Genomes; mLMF, mouse liver macrophages; mBMDM, mouse bone marrow-derived macrophages; mRNA, messenger RNA; ORM2, orosomucoid 2; RNA-seq, RNA sequencing. Unpaired Student’s t-tests were used. *Represents p<0.05.CC BY · PubMed Central
Figure 5 ORM2 reshapes secretome profiles in liver macrophages. (A) Significantly upregulated and downregulated DEGs (encoding secreted proteins) in mLMF by bulk RNA-seq analysis were illustrated in the volcano plot (ORM2-treated vs Ctrl). (B) Gene expression and (C) cytokine concentration of several inflammatory cytokines in mLMF were illustrated (ORM2-treated vs Ctrl). (D) Ligand-receptor prediction from ORM2-activated mLMF were depicted in a flow chart. (E) Function and cell type enrichments were depicted in a flow chart. Sample sizes: (A and B) ORM2-treated (n=4) versus Ctrl (n=5); (C) n=4 per group. DEGs, differentially expressed genes; IL, interleukin; KEGG, Kyoto Encyclopedia of Genes and Genomes; mLMF, mouse liver macrophages; ORM2, orosomucoid 2; RNA-seq, RNA sequencing; TNF, tumour necrosis factor. Unpaired Student’s t-tests were used. *Represents p<0.05.
Figure 5 ORM2 reshapes secretome profiles in liver macrophages. (A) Significantly upregulated and downregulated DEGs (encoding secreted proteins) in mLMF by bulk RNA-seq analysis were illustrated in the volcano plot (ORM2-treated vs Ctrl). (B) Gene expression and (C) cytokine concentration of several inflammatory cytokines in mLMF were illustrated (ORM2-treated vs Ctrl). (D) Ligand-receptor prediction from ORM2-activated mLMF were depicted in a flow chart. (E) Function and cell type enrichments were depicted in a flow chart. Sample sizes: (A and B) ORM2-treated (n=4) versus Ctrl (n=5); (C) n=4 per group. DEGs, differentially expressed genes; IL, interleukin; KEGG, Kyoto Encyclopedia of Genes and Genomes; mLMF, mouse liver macrophages; ORM2, orosomucoid 2; RNA-seq, RNA sequencing; TNF, tumour necrosis factor. Unpaired Student’s t-tests were used. *Represents p<0.05.CC BY · PubMed Central
Figure 6 ORM2 promotes phagocytosis, lipid deposition and cell stress in liver macrophages. (A) Gene expression of Cd163, Timd4, Cyp2e1, Cd36, Cdkn1a and Casp1 in mLMF on ORM2 treatments (0, 0.5, 1.0, 2.0 and 4.0 µg/mL) was measured (ORM2-treated vs Ctrl). (B) Phagocytosis/bead capture (YG+) of mLMF on Ctrl, ORM2 and LPS treatments was illustrated in fluorescent staining and (C) quantitative analysis. (D) Protein expression of TIM4 in mLMF on Ctrl, ORM2 and LPS treatments was illustrated in fluorescent staining and (E) quantitative analysis. (F) Lipid deposition of mLMF on Ctrl, ORM2, FFAs and FFAs+ORM2 treatments was illustrated in fluorescent staining and (G) quantitative analysis. (H) Protein expression of CD36 in mLMF on Ctrl, ORM2 and LPS treatments was assessed by western blot in two independent experiments (both displayed) and (I) quantitative analysis was performed. (J) DNA damage (Sa-β-Gal+) of mLMF on Ctrl, ORM2 and LPS treatments was illustrated in fluorescent staining and (K) quantitative analysis. (L) Cell apoptosis (Apopxin+) of mLMF on Ctrl, ORM2 and LPS treatments was illustrated in fluorescent staining and (M) quantitative analysis. Sample sizes: n=3–4 per group. CD36, cluster of differentiation 36; FFAs, free fatty acids; ITPR2, inositol 1,4,5-trisphosphate receptor type 2; LPS, lipopolysaccharides; mLMF, mouse liver macrophages; ORM2, orosomucoid 2; SA-β-Gal, senescence-associated beta-galactosidase; TIM4, T-cell/transmembrane immunoglobulin and mucin domain containing 4; YG, yellow green fluorescence. One-way analysis of variance followed by Tukey’s multiple comparison tests were performed. *p<0.05 as indicated or as compared with controls.
Figure 6 ORM2 promotes phagocytosis, lipid deposition and cell stress in liver macrophages. (A) Gene expression of Cd163, Timd4, Cyp2e1, Cd36, Cdkn1a and Casp1 in mLMF on ORM2 treatments (0, 0.5, 1.0, 2.0 and 4.0 µg/mL) was measured (ORM2-treated vs Ctrl). (B) Phagocytosis/bead capture (YG+) of mLMF on Ctrl, ORM2 and LPS treatments was illustrated in fluorescent staining and (C) quantitative analysis. (D) Protein expression of TIM4 in mLMF on Ctrl, ORM2 and LPS treatments was illustrated in fluorescent staining and (E) quantitative analysis. (F) Lipid deposition of mLMF on Ctrl, ORM2, FFAs and FFAs+ORM2 treatments was illustrated in fluorescent staining and (G) quantitative analysis. (H) Protein expression of CD36 in mLMF on Ctrl, ORM2 and LPS treatments was assessed by western blot in two independent experiments (both displayed) and (I) quantitative analysis was performed. (J) DNA damage (Sa-β-Gal+) of mLMF on Ctrl, ORM2 and LPS treatments was illustrated in fluorescent staining and (K) quantitative analysis. (L) Cell apoptosis (Apopxin+) of mLMF on Ctrl, ORM2 and LPS treatments was illustrated in fluorescent staining and (M) quantitative analysis. Sample sizes: n=3–4 per group. CD36, cluster of differentiation 36; FFAs, free fatty acids; ITPR2, inositol 1,4,5-trisphosphate receptor type 2; LPS, lipopolysaccharides; mLMF, mouse liver macrophages; ORM2, orosomucoid 2; SA-β-Gal, senescence-associated beta-galactosidase; TIM4, T-cell/transmembrane immunoglobulin and mucin domain containing 4; YG, yellow green fluorescence. One-way analysis of variance followed by Tukey’s multiple comparison tests were performed. *p<0.05 as indicated or as compared with controls.CC BY · PubMed Central
Figure 7 Multiplex immunofluorescence and single-cell transcriptomics reveal heterogeneous ITPR2 expression in liver macrophages during liver diseases. (A) Multiplex immunofluorescence was applied to identify hepatocytes (HepPar1+), cholangiocytes (CK7+) and macrophages (IBA1+), together with ITPR2 expression in human normal, PSC, MASLD-F2 and MASH-F4 liver samples. Red arrows point toward ITPR2-expressing macrophages. (B) Large scan multiplex immunofluorescence images shown in (A) were used for CK7+ and IBA1+ cell distribution analysis (heatmaps), and singular IBA1+ cell relative staining intensities for ITPR2, CD16 and CD163 (dot plots, green: high staining intensity, blue: low staining intensity). (C) Spearman’s correlation was used to evaluate the correlation between single cell immunostaining intensities of the indicated proteins in IBA1+ cells present in the images shown in panels A and B. All markers showed significant correlations. Differential gene expressions were investigated in the indicated data sets for ITPR2, CALM1 and CALM2 in monocyte and macrophage populations in human (D) MASH, (E) PSC and (F) liver cirrhosis (all vs healthy). F2/4, fibrosis stage 2/4; KC, Kupffer cells; ITPR2, inositol 1,4,5-trisphosphate receptor type 2; MASH, metabolic dysfunction-associated steatohepatitis; MASLD, metabolic dysfunction-associated steatotic liver disease; MF, macrophages; Mono: monocytes; PSC, primary sclerosing cholangitis; sc/snRNA-seq, single cell/single nuclei RNA sequencing. (D–F) Unpaired Student’s t-tests were used. *Represents p<0.05.
Figure 7 Multiplex immunofluorescence and single-cell transcriptomics reveal heterogeneous ITPR2 expression in liver macrophages during liver diseases. (A) Multiplex immunofluorescence was applied to identify hepatocytes (HepPar1+), cholangiocytes (CK7+) and macrophages (IBA1+), together with ITPR2 expression in human normal, PSC, MASLD-F2 and MASH-F4 liver samples. Red arrows point toward ITPR2-expressing macrophages. (B) Large scan multiplex immunofluorescence images shown in (A) were used for CK7+ and IBA1+ cell distribution analysis (heatmaps), and singular IBA1+ cell relative staining intensities for ITPR2, CD16 and CD163 (dot plots, green: high staining intensity, blue: low staining intensity). (C) Spearman’s correlation was used to evaluate the correlation between single cell immunostaining intensities of the indicated proteins in IBA1+ cells present in the images shown in panels A and B. All markers showed significant correlations. Differential gene expressions were investigated in the indicated data sets for ITPR2, CALM1 and CALM2 in monocyte and macrophage populations in human (D) MASH, (E) PSC and (F) liver cirrhosis (all vs healthy). F2/4, fibrosis stage 2/4; KC, Kupffer cells; ITPR2, inositol 1,4,5-trisphosphate receptor type 2; MASH, metabolic dysfunction-associated steatohepatitis; MASLD, metabolic dysfunction-associated steatotic liver disease; MF, macrophages; Mono: monocytes; PSC, primary sclerosing cholangitis; sc/snRNA-seq, single cell/single nuclei RNA sequencing. (D–F) Unpaired Student’s t-tests were used. *Represents p<0.05.CC BY · PubMed Central
Figure 8 ORM2 alters macrophage functions via ITPR2/CALMs-dependent calcium pathway. (A) Intracellular calcium levels of mLMF on Ctrl, ORM2, LPS and 2-APB treatments were measured. (B) Gene expression of Calm1/2/3/4 in mLMF was illustrated from bulk RNA sequencing analysis (ORM2-treated vs Ctrl). (C) Protein expression of CALM1/2/3 in mLMF was illustrated in fluorescent staining and (D) quantitative analyses (ORM2-treated vs Ctrl). (E) Protein expression of ITPR2 in mLMF on Ctrl, siCtrl and siItpr2 transfection was illustrated in fluorescent staining and (F) quantitative analyses. (G) Gene expression of Itpr2 in mLMF on Ctrl, siCtrl and siItpr2 transfection was measured. (H) Gene expression of Calm1 and Calm2 in mLMF on Ctrl, siCtrl and siItpr2 transfection was measured. (I) Protein expression of CALM1/2/3/4 in mLMF on Ctrl, siCtrl and siItpr2 transfection was illustrated in fluorescent staining and (J) quantitative analyses. (K) Intracellular calcium levels of mLMF on Ctrl, siCtrl and siItpr2 transfection were measured. (L) Phagocytosis/bead capture (YG+) of mLMF on siCtrl, siCtrl+ORM2, siItpr2 and siItpr2+ORM2 was illustrated in fluorescent staining and (M) quantitative analysis. (N) Protein expression of TIM4 in mLMF on siCtrl, siCtrl+ORM2, siItpr2 and siItpr2+ORM2 was illustrated in fluorescent staining and (O) quantitative analysis. (P) Lipid deposition of mLMF on siCtrl, siCtrl+ORM2, siItpr2 and siItpr2+ORM2 was illustrated in fluorescent staining and (Q) quantitative analysis. Sample sizes: n=3–4 per group. 2-APB, 2-aminoethoxydiphenyl borate; CALM, calmodulin; ITPR2, inositol 1,4,5-trisphosphate receptor 2; LPS, lipopolysaccharides; mLMF, mouse liver macrophages; ORM2, orosomucoid 2; TIM4, T-cell/transmembrane immunoglobulin and mucin domain containing 4; YG, yellow green fluorescence. One-way analysis of variance followed by Tukey’s multiple comparison tests were performed. *p<0.05 as indicated or as compared with controls.
Figure 8 ORM2 alters macrophage functions via ITPR2/CALMs-dependent calcium pathway. (A) Intracellular calcium levels of mLMF on Ctrl, ORM2, LPS and 2-APB treatments were measured. (B) Gene expression of Calm1/2/3/4 in mLMF was illustrated from bulk RNA sequencing analysis (ORM2-treated vs Ctrl). (C) Protein expression of CALM1/2/3 in mLMF was illustrated in fluorescent staining and (D) quantitative analyses (ORM2-treated vs Ctrl). (E) Protein expression of ITPR2 in mLMF on Ctrl, siCtrl and siItpr2 transfection was illustrated in fluorescent staining and (F) quantitative analyses. (G) Gene expression of Itpr2 in mLMF on Ctrl, siCtrl and siItpr2 transfection was measured. (H) Gene expression of Calm1 and Calm2 in mLMF on Ctrl, siCtrl and siItpr2 transfection was measured. (I) Protein expression of CALM1/2/3/4 in mLMF on Ctrl, siCtrl and siItpr2 transfection was illustrated in fluorescent staining and (J) quantitative analyses. (K) Intracellular calcium levels of mLMF on Ctrl, siCtrl and siItpr2 transfection were measured. (L) Phagocytosis/bead capture (YG+) of mLMF on siCtrl, siCtrl+ORM2, siItpr2 and siItpr2+ORM2 was illustrated in fluorescent staining and (M) quantitative analysis. (N) Protein expression of TIM4 in mLMF on siCtrl, siCtrl+ORM2, siItpr2 and siItpr2+ORM2 was illustrated in fluorescent staining and (O) quantitative analysis. (P) Lipid deposition of mLMF on siCtrl, siCtrl+ORM2, siItpr2 and siItpr2+ORM2 was illustrated in fluorescent staining and (Q) quantitative analysis. Sample sizes: n=3–4 per group. 2-APB, 2-aminoethoxydiphenyl borate; CALM, calmodulin; ITPR2, inositol 1,4,5-trisphosphate receptor 2; LPS, lipopolysaccharides; mLMF, mouse liver macrophages; ORM2, orosomucoid 2; TIM4, T-cell/transmembrane immunoglobulin and mucin domain containing 4; YG, yellow green fluorescence. One-way analysis of variance followed by Tukey’s multiple comparison tests were performed. *p<0.05 as indicated or as compared with controls.CC BY · PubMed Central
Figure 9 ORM2-activated liver macrophages suppress biliary cell repair. (A) 5-day kinetics of Mdr2−/− Od-mBEC numbers on Ctrl, ORM2, CM from Ctrl mLMF and ORM2-treated mLMF were measured. (B) Cell proliferation (Ki67+) and apoptosis (Apopxin+) in Mdr2−/− Od-mBECs on Ctrl, ORM2, CM from Ctrl mLMF and ORM2-treated mLMF was investigated by fluorescent staining and (C) quantitative analyses. (D) Gene expressions of Mki67, Ccne1, Cdkn1a, Tjp1, Cldn1, Ocln and Orm2 in Mdr2−/− Od-mBECs on Ctrl, ORM2, CM from Ctrl mLMF and ORM2-treated mLMF were measured. (E) Protein expression of ORM2 in mouse primary BECs on Ctrl, ORM2, CM from Ctrl mLMF and ORM2-treated mLMF was illustrated in fluorescent staining and (F) quantitative analyses. Patient (liver fibrosis stage 0 and 4)-derived hICOs (one line per disease condition) were obtained and cultivated. (G) Morphology of patient (liver fibrosis stage 0 and 4)-derived hICOs on Ctrl, ORM2, CM from Ctrl human MoMF and ORM2-treated human MoMF was illustrated. (H) Gene expressions of MKI67, ORM2 and CCL2 in patient (liver fibrosis stage 0 and 4)-derived hICOs were measured (F4 vs F0). (I) Cell proliferation (Ki67+) and apoptosis (TUNEL+) in patient (liver fibrosis stage 0 and 4)-derived hICOs on Ctrl, ORM2, CM from Ctrl human MoMF and ORM2-treated human MoMF was illustrated in fluorescent staining and (J) quantitative analyses. (K) Gene expressions of MKI67, CCNE1, CDKN1A, TJP1, CLDN1, OCLN and ORM2 in patient (liver fibrosis stage 0 and 4)-derived hICOs on Ctrl, ORM2, CM from Ctrl human MoMF and ORM2-treated human MoMF were measured (vs Ctrl). Sample sizes: n=3 (technical replicates) per group. CM, conditioned medium; F0/4, fibrosis stage 0/4; hICO, human intrahepatic cholangiocyte organoids; mBEC, mouse biliary epithelial cell; mLMF, mouse liver macrophages (-derived conditioned medium); MoMF, monocyte-derived macrophages (-derived conditioned medium); Od, organoid-derived; ORM2, orosomucoid 2; TUNEL, Terminal Deoxynucleotidyl Transferase-Mediated dUTP Nick End Labelling; WT, wild type. One-way analysis of variance followed by Tukey’s multiple comparison tests were performed. ‘*’represents statistical significance in comparison between MoMF-Ctrl versus Ctrl. ‘$’ represents significant differences between MoMF-ORM2 versus MoMF-Ctrl. p<0.05 as indicated or as compared with controls.
Figure 9 ORM2-activated liver macrophages suppress biliary cell repair. (A) 5-day kinetics of Mdr2−/− Od-mBEC numbers on Ctrl, ORM2, CM from Ctrl mLMF and ORM2-treated mLMF were measured. (B) Cell proliferation (Ki67+) and apoptosis (Apopxin+) in Mdr2−/− Od-mBECs on Ctrl, ORM2, CM from Ctrl mLMF and ORM2-treated mLMF was investigated by fluorescent staining and (C) quantitative analyses. (D) Gene expressions of Mki67, Ccne1, Cdkn1a, Tjp1, Cldn1, Ocln and Orm2 in Mdr2−/− Od-mBECs on Ctrl, ORM2, CM from Ctrl mLMF and ORM2-treated mLMF were measured. (E) Protein expression of ORM2 in mouse primary BECs on Ctrl, ORM2, CM from Ctrl mLMF and ORM2-treated mLMF was illustrated in fluorescent staining and (F) quantitative analyses. Patient (liver fibrosis stage 0 and 4)-derived hICOs (one line per disease condition) were obtained and cultivated. (G) Morphology of patient (liver fibrosis stage 0 and 4)-derived hICOs on Ctrl, ORM2, CM from Ctrl human MoMF and ORM2-treated human MoMF was illustrated. (H) Gene expressions of MKI67, ORM2 and CCL2 in patient (liver fibrosis stage 0 and 4)-derived hICOs were measured (F4 vs F0). (I) Cell proliferation (Ki67+) and apoptosis (TUNEL+) in patient (liver fibrosis stage 0 and 4)-derived hICOs on Ctrl, ORM2, CM from Ctrl human MoMF and ORM2-treated human MoMF was illustrated in fluorescent staining and (J) quantitative analyses. (K) Gene expressions of MKI67, CCNE1, CDKN1A, TJP1, CLDN1, OCLN and ORM2 in patient (liver fibrosis stage 0 and 4)-derived hICOs on Ctrl, ORM2, CM from Ctrl human MoMF and ORM2-treated human MoMF were measured (vs Ctrl). Sample sizes: n=3 (technical replicates) per group. CM, conditioned medium; F0/4, fibrosis stage 0/4; hICO, human intrahepatic cholangiocyte organoids; mBEC, mouse biliary epithelial cell; mLMF, mouse liver macrophages (-derived conditioned medium); MoMF, monocyte-derived macrophages (-derived conditioned medium); Od, organoid-derived; ORM2, orosomucoid 2; TUNEL, Terminal Deoxynucleotidyl Transferase-Mediated dUTP Nick End Labelling; WT, wild type. One-way analysis of variance followed by Tukey’s multiple comparison tests were performed. ‘*’represents statistical significance in comparison between MoMF-Ctrl versus Ctrl. ‘$’ represents significant differences between MoMF-ORM2 versus MoMF-Ctrl. p<0.05 as indicated or as compared with controls.CC BY · PubMed Central
Figure 10 ORM2-activated liver macrophages may promote fibrogenesis in HSCs and ORM2 production in hepatocytes. (A) Gene expression of Acta2, Col1a1, Tgfb1 and Pdgfrb in mouse HSCs and Ccne1, Cdkn1a, Alb, Cyp2e1, Orm2 and Mki67 in mouse hepatocytes on Ctrl, ORM2, CM from Ctrl mLMF and ORM2-treated mLMF were measured. (B) Cell accumulation (F-Actin+) and collagen production (COL1A1+) in mouse HSCs (cultivated in non-collagen-coated plates) on Ctrl, ORM2, CM from Ctrl mLMF and ORM2-treated mLMF were illustrated by fluorescent staining and (C) quantitative analyses. (D) Cell identification (Desmin+) and activation (α-SMA+) in mouse HSCs (cultivated in collagen-coated plates) on Ctrl, ORM2, CM from Ctrl mLMF and ORM2-treated mLMF were illustrated in fluorescent staining and (E) quantitative analyses. (F) Protein expression of ORM2 in mouse hepatocytes on Ctrl, ORM2, CM from Ctrl mLMF and ORM2-treated mLMF were illustrated in fluorescent staining and (G) quantitative analyses. Sample sizes: (A, C, E and G) n=4 per group. CM, conditioned medium; COL1A1, collagen type I alpha 1 chain; (m)HepaC, (mouse) hepatocyte; (m)HSC, (mouse) hepatic stellate cell; (m)LMF, (mouse) liver macrophages (-derived conditioned medium); mRNA, messenger RNA; ORM2, orosomucoid 2; α-SMA, alpha smooth muscle actin. One-way analysis of variance followed by Tukey’s multiple comparison tests were performed. ‘*’ represents statistical significance in comparison between mLMF-Ctrl versus Ctrl. ‘$’ represents statistical significance in comparison (mLMF-ORM2 vs mLMF-Ctrl). p<0.05 as indicated or as compared with controls.
Figure 10 ORM2-activated liver macrophages may promote fibrogenesis in HSCs and ORM2 production in hepatocytes. (A) Gene expression of Acta2, Col1a1, Tgfb1 and Pdgfrb in mouse HSCs and Ccne1, Cdkn1a, Alb, Cyp2e1, Orm2 and Mki67 in mouse hepatocytes on Ctrl, ORM2, CM from Ctrl mLMF and ORM2-treated mLMF were measured. (B) Cell accumulation (F-Actin+) and collagen production (COL1A1+) in mouse HSCs (cultivated in non-collagen-coated plates) on Ctrl, ORM2, CM from Ctrl mLMF and ORM2-treated mLMF were illustrated by fluorescent staining and (C) quantitative analyses. (D) Cell identification (Desmin+) and activation (α-SMA+) in mouse HSCs (cultivated in collagen-coated plates) on Ctrl, ORM2, CM from Ctrl mLMF and ORM2-treated mLMF were illustrated in fluorescent staining and (E) quantitative analyses. (F) Protein expression of ORM2 in mouse hepatocytes on Ctrl, ORM2, CM from Ctrl mLMF and ORM2-treated mLMF were illustrated in fluorescent staining and (G) quantitative analyses. Sample sizes: (A, C, E and G) n=4 per group. CM, conditioned medium; COL1A1, collagen type I alpha 1 chain; (m)HepaC, (mouse) hepatocyte; (m)HSC, (mouse) hepatic stellate cell; (m)LMF, (mouse) liver macrophages (-derived conditioned medium); mRNA, messenger RNA; ORM2, orosomucoid 2; α-SMA, alpha smooth muscle actin. One-way analysis of variance followed by Tukey’s multiple comparison tests were performed. ‘*’ represents statistical significance in comparison between mLMF-Ctrl versus Ctrl. ‘$’ represents statistical significance in comparison (mLMF-ORM2 vs mLMF-Ctrl). p<0.05 as indicated or as compared with controls.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 67 references

Cited by

See all 24

Metadata

Authors
Liu, H., Yin, G., Franco Leonardi, B., Lan, T., Ait Ahmed, Y., Berger, H., Kohlhepp, M. S., Amiridze, N., Martagón Calderón, N., Frau, C., Vallier, L., Rezvani, M., Tacke, F., & Guillot, A.
Affiliations
  • National Institutes of Health (US)
  • Charité – Universitätsmedizin Berlin (DE)
  • Department of Hepatology and Gastroenterology, Campus Virchow-Klinikum and Campus Charité Mitte, Charité - Universitätsmedizin Berlin, Berlin, BE, Germany
  • Sichuan University (CN)
  • Department of Pediatric Gastroenterology, Nephrology and Metabolic Medicine, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany
  • Berlin-Brandenburger Centrum für Regenerative Therapien (DE)
  • Humboldt-Universität zu Berlin (DE)
  • Stiftung Charité (DE)
Corresponding author
Guillot, Adrien
Venue
Gut
Publisher
BMJ
Published
2025-04-08
Volume
74
Issue
10
Pages
1694-1710
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
OpenAlex
W4409263718
Cited by
23
References
67
Citations by year
2026: 11 · 2025: 12
FWCI
12.93
Type
journal article
Language
en
Open access
Locations
  • Gut (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • MPG.PuRe (Max Planck Society) (submittedVersion, other-oa)
  • RWTH Publications (RWTH Aachen)
Funders
  • Fundação de Amparo à Pesquisa do Estado de São Paulo (2024/06344-8)
  • China Scholarship Council (202008320386, 202206240096, 202208320084)
  • Luise and Horst Köhler Foundation (A4R-2023-02-BA)
  • National Natural Science Foundation of China (82300730)
  • Deutsche Forschungsgemeinschaft (Emmy Noether Program, Project-ID 437638965, SFB1382, Project-ID 403224013, Ta434/8-1)
Topics
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
Keywords
ORM2, ductular reaction, hepatic stellate cell activation, liver fibrosis, acute phase response, calcium signaling, paracrine signaling, cholangiocyte organoids, MDR2, liver injury
MeSH terms
Animals, Disease Models, Animal, Epithelial Cells, Humans, Liver, Macrophages, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Reactive cholangiocyte-derived ORM2 drives a pathogenic modulation of the injured biliary niche through macrophage reprogramming. https://app.cochat.ai/papers/10.1136/gutjnl-2024-334425
The paper
Liu, H., Yin, G., Franco Leonardi, B., Lan, T., Ait Ahmed, Y., Berger, H., Kohlhepp, M. S., Amiridze, N., Martagón Calderón, N., Frau, C., Vallier, L., Rezvani, M., Tacke, F., & Guillot, A. (2025). Reactive cholangiocyte-derived ORM2 drives a pathogenic modulation of the injured biliary niche through macrophage reprogramming. Gut. https://doi.org/10.1136/gutjnl-2024-334425

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.